EUCTR2014-005484-32-SE进行中（未招募）不适用
Double-blind, randomized placebo controlled study on the effect from cortisone treatment of vestibular neuritis - function, subjective well-being and stress
und University0 个研究点开始时间: 2015年3月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-between 18 and 80 years of age
- •-disease duration <48hrs
- •-clinical vestibular neuritis and no other neurological symptoms
- •-no dangerous HINTS (examination procedure)
- •-informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •-history of perforated ulcus
- •-tinnitus and hearing loss that started at the same time as vertigo
- •-psychiatric disease requiring treatment (other than mild depression treated with SSRIs)
- •-chronic otitis media
- •-serious infection, neutropenia or tuberculosis
- •-pregnancy or not wanting to prevent pregnancy during the time of medication (11 days)
- •-blood pressure; systolic >180 and/or diastolic >110
- •-impaired ability to make decision (dementia or up to treating physician)
- •-diabetes with ketoacidosis (Base excess >=2)
研究者
相似试验
进行中（未招募）
1 期
Double-blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone. - TADTESTErectile dysfunctionClassification code 10061461EUCTR2005-000852-34-GBSELARL du Dr Jacques BUVAT430
已完成
不适用
Clinical study of IND02 on side effects of breast cancer chemotherapyCTRI/2012/08/002883Indus Biotech Private Limited34
招募中
不适用
Double-blind, randomized, placebo controlled study to REduce STEroids in Relapsing Nephrotic syndromeNL-OMON47536Radboud Universitair Medisch Centrum80
进行中（未招募）
1 期
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000013775EUCTR2012-000066-37-CZordmark Arzneimittel GmbH & Co. KG115
进行中（未招募）
1 期
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000004854EUCTR2012-000066-37-DEordmark Arzneimittel GmbH & Co. KG115